Innova Captab Ltd Q1FY26 – P/E 37.7, EV/EBITDA 24.5, Zero Dividend but 35.7% Profit CAGR in 5 Years
1. At a Glance
Innova Captab Ltd – the pharma kid from 2005 that decided, “Why just make tablets when you can swallow the entire value chain?” – is now strutting around Dalal Street with a ₹4,889 crore market cap. At ₹853 per share, the stock is closer to its 52-week low (₹662) than its high (₹1,260), like a cricketer who once hit a century but is now struggling in the Ranji Trophy. Despite a P/E of 37.7 and EV/EBITDA of 24.5, the company insists it’s worth the premium, courtesy of 35.7% profit CAGR in the last five years and a brand-new ₹450 crore Jammu facility that promises to mint ₹400–500 crore in FY26 revenues. ROE is a decent 14.3%, promoters hold a steady 50.9%, and FIIs… well, they’ve ghosted harder than Tinder matches (down to 0.23%). The company is profitable but allergic to dividends, preferring to hoard cash for expansion like a desi uncle stocking Maggi during lockdown.
2. Introduction
Imagine a pharma company that wants to be everything everywhere all at once – contract manufacturer, branded generics player, global exporter, and acquirer of bankrupt assets (hi Sharon Bio-Medicine). That’s Innova Captab. They started in 2005 in Himachal with one block and now operate nine blocks across Baddi, Dehradun, Taloja, and Jammu. If pharma were a joint family business, Innova is that over-enthusiastic cousin who not only manages the kirana shop but also opens a coaching center, starts a Zomato cloud kitchen, and buys a failing gym – just in case.
Their CDMO business serves 14 of India’s top 15 pharma companies – Cipla, Lupin, Ajanta, Glenmark, basically everyone except maybe your local chemist uncle. Domestic branded generics? They’ve got 600 products across therapies – so chances are, if you ever swallowed a strip of something ending with “-azole,” “-statin,” or “-cillin,” it might have passed through their conveyor belts. Internationally, they’re shipping to 25 countries, and thanks to Sharon, they’ve entered regulated markets like Canada, UK, and Europe.
But here’s the twist – 75% of their revenues come from exports. So while they’re headquartered in India, their heart (and wallet) beats for foreign regulators. Add a GST incentive scheme (300% on plant investment for 10 years) and a planned R&D lab in Panchkula, and suddenly the picture looks less like a sleepy Himachali CDMO and more like a desi company practicing yoga stretches before a long global sprint.
3. Business Model – WTF Do They Even Do?
Okay, let’s break it down without pharma-jargon. Innova Captab is like a wedding caterer who also decides to open his own restaurant, supply spices to other caterers, and acquire a struggling 5-star hotel on the side.
CDMO (55% of revenue): Think of it as contract marriage halls – companies like Cipla or Lupin outsource the messy work of production to Innova. They develop, manufacture, and even provide regulatory support. With 2,900+ products and 190+ clients, it’s basically “Swiggy for pills.”
Domestic Branded Generics (18%): Here they push their own labels into pharmacies – like a caterer selling ready-made gulab jamuns under his own name. With 600+ products across therapies, they’ve reached 1.5 lakh pharmacies, i.e., every nook where your local chemist sits on a plastic chair under a dusty tube light.
International Branded Generics (12%): Exports to 25 countries, mostly in Asia, Africa, and Latin America. Because why not sell paracetamol with a Spanish accent if margins are better?
Sharon Business (15%): Acquired in June 2023 during insolvency proceedings. Sharon specializes in international formulations and APIs, targeting highly regulated markets. This is like marrying someone with baggage but discovering they have a London flat deed tucked in the cupboard.
Revenue mix (9MFY25) screams diversification, but also raises a question: Is this company spreading itself too thin? Or is it genuinely becoming the Reliance of pharma – one day CDMO, next day branded play, and soon maybe retail chemist chains?
👉 Before I go further: If a company is making money from Cipla, Lupin, and Ajanta while also trying to be Cipla, Lupin, and Ajanta… what could possibly go wrong?
4. Financials Overview
Here’s the scoreboard of the latest quarter (Q1 FY26 vs. others):
